Abstract 1887P
Background
Palliative care patients experience chronic sorrow due to living loss such as impairment in bodily functions, inability to carry out daily life, and meaninglessness due to impending death. Logotherapy was shown to be an effective method to cope with end-of-life related distress. The aim of this study was to investigate effectiveness of logotherapy on chronic sorrow, dignity, and meaning in life on palliative care patients.
Methods
This randomized-controlled study was conducted between September 2021-June 2023 in medical and gynecological oncology clinics of a university hospital, with 58 adult advanced cancer patients requiring palliative care. Participants were assigned to either intervention (n=29) or control (n=29) group by simple randomization via a computer program. Participants, ≥18 years old, having advanced solid cancer, aware of their diagnosis, having no communication problem or mental disorder, with a life expectancy over 6 months and Palliative Performance Scale score ≥%50, and verbally expressing to experience chronic sorrow were included. Data were collected with demographic form, Patient Dignity Inventory (PDI), Prolonged Grief Disorder Scale-Patient Form (PGD-PF), presence of meaning (MIL-PM) and search for meaning (MIL-SM) subdimensions of Meaning in Life (MIL) Questionnaire. Data were collected on admission, at the 4th and 8th weeks. Intervention group received logotherapy, lasting about of 45 minutes, 2 days a week for 4 weeks. Control group received routine care.
Results
The mean scores of PDI (p=0.01), PGD-PF (p=0.01) and MIL-SM (p=0.11) were lower in the intervention group, while MIL-PM was higher (p=0.02). Within group analysis showed a decrease in PDI (p<0.01), PGD-PF (p=0.01), MIL-SM (p=0.02), and increase in MIL-PM (p<0.01) in the intervention group while mean scores of PDI (p=0.01), PGD-PF (p=0.01), MIL-SM (p=0.04), and MIL-PM (p=0.05) decreased in control group.
Conclusions
Logotherapy was found effective on decreasing sorrow and dignity related distress of palliative care patients, while increasing finding meaning in life.
Clinical trial identification
NCT05129059.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1950P - Squamous cell carcinoma of unknown primary (SCCUP): A genomic landscape study
Presenter: Hannah Robinson
Session: Poster session 12
1951P - A multicenter, retrospective study of non-small-cell lung carcinoma (NSCLC) harboring EGFR exon 20 insertions: Distribution, variants, and prevalence of coalterations
Presenter: Ivana Gabriela Sullivan
Session: Poster session 12
1952P - Multiomic spatial profiling of whole-slide NSCLC tissues from patients receiving anti PD-1 therapy identifies metabolic phenotypes associated with therapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 12
1953P - The ATXN3-USP25-TRMT1 axis regulates tRNAm2,2G modification and promotes osimertinib resistance in lung cancer
Presenter: Tianqing Chu
Session: Poster session 12
Resources:
Abstract